Figure 7.
![Monitoring of molecular and cytogenetic alterations in 7 patients with MDS. Five patients receiving treatment (3 azacitidine, 1 FLAG-IDA+HCT, and 1 HIF [hypoxia-inducible factor inhibitor]) and 2 untreated cases were included. BM VAF dynamics are shown with dotted lines and cfDNA dynamics are shown with solid lines. CMML, chronic myelomonocytic leukemia; CNA, copy number alteration; HCT, hematopoietic cell transplantation; ND, not detected.](https://ash.silverchair-cdn.com/ash/content_public/journal/bloodadvances/6/10/10.1182_bloodadvances.2021006565/3/advancesadv2021006565f7.png?Expires=1719457256&Signature=VjDWtMFMdQc-VVwWjcwjmJnEwX0skJhMKYDIPwatHMQ3NUmHS-tcNBsGCIMZKCrSUU~arLRql42ye11KEyNNLvAgNerHvOJfrlx5q3RuoS7Ex4lK2s-hExepeFxXjPMmZVfUht8N35dWXnhaLeZCagkYeLwEMVGFZNFmNXC1PJbtzUhLsuSz2-VBhPGWQhw4-J1E~H3rgDtiTYoupYpwXnpq027aUNSVrxeO4~d-dIAQAlJMTMshceMZBXl-LQ789IU4LLcCRbqDq-9y5KqQ4qy970~eAL-VyqJhlwsoFxq1QakWMIpPASRjjbaGgAf9JQdam46RXRnEKxZCbyRvyQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Monitoring of molecular and cytogenetic alterations in 7 patients with MDS. Five patients receiving treatment (3 azacitidine, 1 FLAG-IDA+HCT, and 1 HIF [hypoxia-inducible factor inhibitor]) and 2 untreated cases were included. BM VAF dynamics are shown with dotted lines and cfDNA dynamics are shown with solid lines. CMML, chronic myelomonocytic leukemia; CNA, copy number alteration; HCT, hematopoietic cell transplantation; ND, not detected.